Microline Surgical designs, develops, manufactures, and markets a broad range of minimally invasive reposable instruments for surgery worldwide.

Microline Group
Founded in 1987, Microline is a wholly owned subsidiary of HOYA Corporation in Tokyo, Japan, a $6.3 billion company with approximately half of its revenue in medical business, including endoscopy and eye care. Microline Surgical designs, develops, manufactures, and markets a broad range of minimally invasive reposable instruments for surgery worldwide.

Founded in 1997, Starion Instruments™ Corp. was acquired by Microline Group in April 2009 and officially merged in October 2011. Microline develops advanced surgical devices that enhance performance, minimize risk and improve patient outcome.

Microline's product portfolio comprises cutting, dissecting, grasping, cauterizing and ligating instruments used in all laparoscopic surgical disciplines, including General Surgery, Gynecologic Surgery, Urologic Surgery, and Bariatric Surgical procedures. All products are FDA cleared and CE marked.

The Company's flagship products are:

  • The ReNew reposable laparoscopic surgical instruments associating various single-patient use, disposable tips with a universal reusable handpiece,
  • The Visu-Loc laparoscopic 5mm single-patient use disposable Clip Applier using an innovative self-ligating clip technology.

Starion's instruments, now Microline's MiFusion product line, employ a patented Thermal Fusion technology that seals and divides soft tissue utilizing only direct heat and pressure. Known for their effectiveness, reliability and versatility, MiFusion products are used worldwide for open and endoscopic Cardiac, Gynecology, General Surgery, Otolaryngology and Urology procedures.

The Microline Group products address a primary market opportunity estimated at $900 million in a global minimally invasive surgery market estimated at about $4 billion. The Group's products are distributed worldwide through a network of over 70 independent distributors in the U.S., Europe, Japan, the Middle-East and Asia. The Group leverages its relationship with its parent company HOYA, by using its sales offices in select Asian territories. In the U.S., Microline is the recipient of 3 contracts with leading Group Purchase Organizations.

Research & Development
The Microline Group invests over 8% of its revenue into Research and Development. Its highly skilled engineers design and develop products in the Company's newly expanded, state-of-the-art, proprietary research facility. The Company has a strong patent portfolio around laparoscopic surgical instruments and is consistently building upon its comprehensive Intellectual Property base.

Manufacturing Facilities
The Company employs 185 collaborators and occupies 50,000 sq ft at its worldwide headquarters located in Beverly, Massachusetts, USA.

Regulatory Affairs and Quality Assurance
Microline is an ISO 13485: 2003 certified company registered with the U.S. Food and Drug Administration (FDA). The facilities are periodically audited by FDA and BSI, the European Notified Body which allows for CE marking of products marketed in the European Union. Every single part, sub-assembly, and finished product of the Company is subjected to multiple quality control inspections at each manufacturing step.